



## Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

November 5, 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Nov. 5, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

**Title:** ADI-001: An Allogeneic CD20-targeted  $\gamma\delta$  CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications

**Session Name:** Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

**Abstract Number:** 1866169

**Presenting Author:** Monica Moreno, Ph.D.

**Date and Time:** November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

### About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241105685914/en/): <https://www.businesswire.com/news/home/20241105685914/en/>

### Adicet Bio., Inc.

#### Investor and Media Contacts

##### Investors:

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Janhavi Mohite

Precision AQ

212-362-1200

[janhavi.mohite@precisionaq.com](mailto:janhavi.mohite@precisionaq.com)

##### Media:

Kerry Beth Daly

[kbdaly@adicetbio.com](mailto:kbdaly@adicetbio.com)

Source: Adicet Bio, Inc.